160 related articles for article (PubMed ID: 36963722)
21. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
[TBL] [Abstract][Full Text] [Related]
22. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation.
Tassi E; Noviello M; De Simone P; Lupo-Stanghellini MT; Doglio M; Serio F; Abbati D; Beretta V; Valtolina V; Oliveira G; Racca S; Campodonico E; Ruggiero E; Clerici D; Giglio F; Lorentino F; Dvir R; Xue E; Farina F; Oltolini C; Manfredi F; Vago L; Corti C; Bernardi M; Clementi M; Brix L; Ciceri F; Peccatori J; Greco R; Bonini C
Haematologica; 2023 Jun; 108(6):1530-1543. PubMed ID: 36200418
[TBL] [Abstract][Full Text] [Related]
24. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D
Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
27. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.
Huang J; Pan Z; Wang L; Zhang Z; Huang J; Jiang C; Cai G; Yin T
Clin Exp Med; 2024 Jan; 24(1):22. PubMed ID: 38280072
[TBL] [Abstract][Full Text] [Related]
28. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
29. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
30. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
31. A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
Zhang P; Yang D; Tian J; Feng S; Jiang E; Han M
Ann Palliat Med; 2021 May; 10(5):5533-5540. PubMed ID: 34107701
[TBL] [Abstract][Full Text] [Related]
32. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
[TBL] [Abstract][Full Text] [Related]
35. QuantiFERON-CMV and monitor predict cytomegalovirus, mortality, and graft-versus-host disease in transplant recipients.
Souan L; Jazar HA; Nashwan S; Sughayer MA
J Med Virol; 2023 Nov; 95(11):e29250. PubMed ID: 38009250
[TBL] [Abstract][Full Text] [Related]
36. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
[TBL] [Abstract][Full Text] [Related]
37. Prior cytomegalovirus reactivation may lead to worse bacterial bloodstream infection outcomes in HSCT patients.
Li S; Xiao Y; Jia M
Transpl Immunol; 2024 Jun; 84():102038. PubMed ID: 38518827
[TBL] [Abstract][Full Text] [Related]
38. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
39. Humoral/Cellular Immune Discordance in Stem Cell Donors: Impact on Cytomegalovirus-Specific Immune Reconstitution after Related Hematopoietic Transplantation.
Valle-Arroyo J; Páez-Vega A; Fernández-Moreno R; López-Jiménez J; Luna A; Duarte R; Serrano-Martínez F; Villar S; Fernández-Alonso M; Reina G; González-Rico C; Fariñas MC; Rojas R; Herrera C; Martín C; García-Torres E; Torre-Cisneros J; Cantisán S
Transplant Cell Ther; 2022 Oct; 28(10):703.e1-703.e8. PubMed ID: 35830929
[TBL] [Abstract][Full Text] [Related]
40. QuantiFERON-cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Thompson G; Boan P; Purtill D; Cooney J; Cannell P; Wright M; John M
Transpl Infect Dis; 2022 Apr; 24(2):e13786. PubMed ID: 34994053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]